The first studies demonstrated that hENT1 expression was prognostic in pancreatic cancer, but this research included both early (resected) and advanced disease, which were mostly treated with gemcitabine (Spratlin et al., 2004; Giovannetti et al., 2006). Here, SLC29A1 is linked to familial pancreatic carcinoma.